Viking Therapeutics (VKTX) Downgraded by BidaskClub

Share on StockTwits

BidaskClub cut shares of Viking Therapeutics (NASDAQ:VKTX) from a sell rating to a strong sell rating in a research report released on Tuesday morning, BidAskClub reports.

VKTX has been the subject of several other research reports. Maxim Group lowered their price objective on shares of Viking Therapeutics from $28.00 to $20.00 and set a buy rating for the company in a research report on Thursday, March 14th. Leerink Swann assumed coverage on shares of Viking Therapeutics in a research report on Friday, February 22nd. They set a market perform rating and a $10.00 price target for the company. William Blair reiterated an outperform rating on shares of Viking Therapeutics in a research report on Friday, March 29th. Svb Leerink assumed coverage on shares of Viking Therapeutics in a research report on Friday, February 22nd. They set a mkt perform rating for the company. Finally, Raymond James lowered their price target on shares of Viking Therapeutics from $43.00 to $40.00 and set a strong-buy rating for the company in a research report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $22.54.

VKTX opened at $8.82 on Tuesday. The stock has a market capitalization of $612.24 million, a price-to-earnings ratio of -22.05 and a beta of 2.75. Viking Therapeutics has a 1-year low of $3.69 and a 1-year high of $24.00.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. Equities research analysts forecast that Viking Therapeutics will post -0.45 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Virtu Financial LLC grew its position in shares of Viking Therapeutics by 844.3% during the 1st quarter. Virtu Financial LLC now owns 163,782 shares of the biotechnology company’s stock worth $1,628,000 after buying an additional 146,438 shares during the period. Woodstock Corp acquired a new stake in shares of Viking Therapeutics during the 1st quarter worth approximately $544,000. Geode Capital Management LLC grew its position in shares of Viking Therapeutics by 30.6% during the 4th quarter. Geode Capital Management LLC now owns 594,510 shares of the biotechnology company’s stock worth $4,548,000 after buying an additional 139,420 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Viking Therapeutics during the 4th quarter worth approximately $1,478,000. Finally, UBS Oconnor LLC grew its position in shares of Viking Therapeutics by 8.3% during the 4th quarter. UBS Oconnor LLC now owns 102,842 shares of the biotechnology company’s stock worth $787,000 after buying an additional 7,842 shares during the period. Institutional investors own 65.35% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Article: What is insider trading?

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Obsidian Trading Down 30.4% This Week
Obsidian Trading Down 30.4% This Week
Monolithic Power Systems  Lowered to “Hold” at BidaskClub
Monolithic Power Systems Lowered to “Hold” at BidaskClub
NPER  Achieves Market Capitalization of $200,708.00
NPER Achieves Market Capitalization of $200,708.00
Bausch Health Companies  Downgraded to “Sell” at ValuEngine
Bausch Health Companies Downgraded to “Sell” at ValuEngine
Innophos  Cut to “Sell” at BidaskClub
Innophos Cut to “Sell” at BidaskClub
Bed Bath & Beyond  Lowered to Sell at BidaskClub
Bed Bath & Beyond Lowered to Sell at BidaskClub


© 2006-2019 Ticker Report